Search clinical trials for: 2B3-201

Total 2305 results

BBB-Therapeutics B.V.

Terminated

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Multiple Sclerosis | Healthy Volunteers

Netherlands
Southwest Regional Wound Care Center

Completed

A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers (WPP-201)

Venous Leg Ulcers

United States
BBB-Therapeutics B.V.

Completed

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Melanoma | Breast Cancer | Lung Cancer | Malignant Glioma | Brain Metastases

United States, Netherlands, France, Belgium
RedHill Biopharma Limited

Completed

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

COVID-19 | Lung Infection

United States, Brazil, Colombia, Israel, Italy, Mexico, Peru, Poland, Russian Federation, United Kingdom
The Netherlands Cancer Institute

Unknown

Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

Meningeal Carcinomatosis

Netherlands
QurAlis Corporation

Recruiting

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Amyotrophic Lateral Sclerosis

Canada, Germany, Netherlands, Ireland, United Kingdom, Belgium
Taipei Veterans General Hospital, Taiwan

Unknown

The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids

Uterine Fibroids

Taiwan
Global Biotech

Completed

Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.

Cerebrovascular Accident

Taiwan
Royal Prince Alfred Hospital, Sydney, Australia

Completed

Evaluation of the Use of Cap in Improving the Performance of Colonoscopy

Colonoscopy

Australia
Tonix Pharmaceuticals, Inc.

Completed

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

Healthy
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer (ARAFOR)

Prostate Cancer

Latvia
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
Suzhou Connect Biopharmaceuticals, Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Atopic Dermatitis

China
Noema Pharma AG

Recruiting

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

Hot Flashes | Menopause | Menopause Syndrome

United States
TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis

Psoriasis

Germany, Israel, Poland, Spain
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Tension-Type Headache

United States
PegBio Co., Ltd.

Completed

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Type2 Diabetes Mellitus

China
ImmuneOncia Therapeutics Inc.

Active, not recruiting

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Extranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK/T-cell Lymphoma

Korea, Republic of
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Prostate Cancer

United States, United Kingdom, Finland, France, Estonia, Czech Republic
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Zhejiang University

Recruiting

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Transthyroxin Amyloidosis Cardiomyopathy

China
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Lumen Bioscience, Inc.

Completed

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

C. Diff. Infections

Australia
Otonomy, Inc.

Completed

Open-Label Study of OTO-201 for Treatment of AOMT

Acute Otitis Media | AOMT

United States
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Finland, France, Czech Republic, Estonia
Beersheva Mental Health Center

Unknown

Neurofeedback Using TMS as an Assessment Tool

Brain Diseases

Israel
Lumos Pharma

Active, not recruiting

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (OraGrowtH213)

Growth Hormone Deficiency

United States, Poland
Evotec Neurosciences GmbH

Completed

Efficacy Study of EVT 201 to Treat Insomnia

Sleep Initiation and Maintenance Disorders

United States
Evotec Neurosciences GmbH

Completed

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

Sleep Initiation and Maintenance Disorders

United States
Proteon Therapeutics

Withdrawn

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)

Chronic Kidney Disease

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess VB-201 in Patients With Psoriasis

Active Plaque Psoriasis

United States, Germany, Israel
Proteon Therapeutics

Completed

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Chronic Kidney Disease

United States, Canada
Proteon Therapeutics

Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Peripheral Artery Disease

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
Atsena Therapeutics Inc.

Recruiting

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

X-linked Retinoschisis

United States
Pyxis Oncology, Inc

Recruiting

Study of PYX-201 in Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, Spain, Belgium
Otonomy, Inc.

Completed

Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Bilateral Middle Ear Effusion

United States
Chase Pharmaceuticals Corporation, an affiliate...

Completed

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Alzheimer's Disease

United States
Chase Pharmaceuticals Corporation, an affiliate...

Completed

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Dementia of the Alzheimer's Type

United States
Proteon Therapeutics
University of California, San Francisco

Completed

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Introgen Therapeutics

Unknown

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Carcinoma, Squamous Cell

United States
Mylan Specialty, LP

Completed

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

Pain | Acute Pain | Post Operative Pain

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece

Search clinical trials for: 2B3-201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations